Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by...
Drug
AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga...
AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure
UK-based pharmaceutical major AstraZeneca plc (AZ, NASDAQ: AZN) has announced that China’s National Medical Products...
MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone
Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study...
HutchMed’s Sovleplenib Achieves Primary and Secondary Endpoints in ESLIM-01 Phase III Trial
China-based biopharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the pivotal...
Grand Pharmaceutical Group Initiates Phase I Study for Sepsis Treatment APAD
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the enrollment and dosing of the...
HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Gastric Cancer
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its MET inhibitor, Orpathys (savolitinib),...
Humanwell Healthcare Initiates Phase IIa Clinical Study for IPF Drug HW021199
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced the commencement of a Phase...
GSK’s RSV Vaccine Arexvy Launches in US Pharmacies Ahead of 2023/24 Season
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has announced that its respiratory syncytial virus...
GC Biopharma Presents Data Showing Higher Thrombotic Risk with Roche’s Hemlibra
South Korea’s GC Biopharma (KRX: 006280) has presented evidence suggesting that Roche’s (SWX: ROG) hemophilia...
Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants
Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2...
Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug
China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...
CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...
Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment
China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...
Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...